[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609078":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":52,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-PSMA-11 PET\u002FCT","EXPERIMENTAL","Intravenous injection of 68Ga-PSMA-11 with a dosage of 111-148 MBq (3-4 mCi), followed by PET\u002FCT or PET\u002FMRI acquisition according to standard methods",[13],"Drug: 68Ga-PSMA-11",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","68Ga-PSMA-11","Intravenous injection of 68Ga-PSMA-11 with a dosage of 111-148 MBq (3-4 mCi), followed by PET\u002FCT or PET\u002FMRI acquisition according to standard methods.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Weibign Miao, MD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Weibing Miao, MD","CONTACT","86-0591-87981618","miaoweibing@126.com",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"Guochang Wang, MD","86-0591-87981619","guochang1007@163.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":45,"coordinates":46},"Point",[47,48],119.30611,26.06139,{"lat":48,"lon":47},[51],{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100609078","phase-2-68ga-psma-11-pet-imaging-for-diagnosing-prostate-cancer-a-head-to-head-comparison-with-mpmri-100609078",false,"NCT07209878","68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI","68Ga-PSMA-11 PET Imaging in the Diagnostic Study of Newly Diagnosed, Untreated Prostate Cancer, With a Head-to-head Comparison to mpMRI","Inclusion Criteria:\n\n* Biopsy-confirmed adenocarcinoma of the prostate.\n* No anti-tumor treatment received prior to the PET imaging.\n* Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.\n* Radical prostatectomy scheduled within 28 days after PET imaging\n\nExclusion Criteria:\n\n* Patients with other malignant tumors\n* Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.","MALE","18 Years","80 Years",{"count":65,"type":66},100,"ESTIMATED","INTERVENTIONAL",[69,70],"PHASE2","PHASE3","68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET\u002FCT or PET\u002FMRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).",[73],"Prostate Cancer (Adenocarcinoma)",[75,76,77,78],"PSMA","Prostate cancer","PET imaging","mpMRI","2025-09-30",{"date":81,"type":82},"2025-10-07","ACTUAL",{"date":84,"type":82},"2020-01-10",{"date":86,"type":66},"2026-06-30",{"name":5,"class":6},1]